ArticleScientific reports2025
High-throughput in vitro screening and in silico analysis for Zika virus inhibitor identification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancement of simeprevir and sofosbuvir anti-ZIKV activity by iNOS-derived NO in vitroFIRST REVIEW ROUND - REVIEWERS' COMMENTSREVIEWERS' COMMENTS.Memorias do Instituto Oswaldo Cruz · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Zika Virus (ZIKV) is a mosquito-borne virus that can cause serious health problems, including birth defects and neurological complications. Unfortunately, there are no antivirals currently approved for its treatments. In this study, we tested a library of 348 chemical compounds to find potential candidates that could block ZIKV infection. Seven compounds showed strong antiviral activity in laboratory experiments. Among them, Cephalotaxine, Docusate Sodium, and Saikosaponin B2 were the most effective. However, Docusate Sodium may pose safety risks at higher doses, and Saikosaponin B2 has poor solubility, which could limit its use as a drug. To better understand how these compounds work, molecular docking was employed to predict interactions between the active compounds and two important ZIKV proteins: NS5 and the NS2B-NS3 protease complex. The docking results supported the in vitro findings, revealing strong binding affinities, particularly for Saikosaponin B2. Molecular dynamics simulations confirmed stable binding of Saikosaponin B2 and Aloperine to NS5, with Saikosaponin B2 showing greater stability and consistent interactions. Drug-likeness and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis indicated that while some compounds possess favorable pharmacokinetic properties, others may require structural optimization. Overall, this study identifies several promising lead compounds for further preclinical development and highlights the utility of integrating in vitro screening with computational modeling to accelerate antiviral drug discovery against ZIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.